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ABSTRACT 
Gangrene of hand leading to its amputation may be the worst after-effects of cisplatin. Here we report the case of cisplatin-induced gangrene in a 
patient of the cancer cervix who was treated with concurrent chemo radiation. 
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INTRODUCTION 
The standard of care for carcinoma cervix FIGO IB-IVA is concurrent 
chemoradiation. The usual practice, globally, is to give Inj. Cisplatin 
at 40 mg/m2
CASE REPORT 
weekly while the patients are on external beam 
radiation. Cisplatin is known to cause nausea, vomiting and 
peripheral neurotoxicity. Here we present a very unusual case of 
cisplatin induced gangrene in the upper limb of a patient of the 
carcinoma cervix who was treated with the standard chemo-
radiation as mentioned above. 
A 45-year-old lady presented with complaints of bleeding and 
discharges per vaginum for few months. On clinical examination, she 
was found to have a bulky ulcero-proliferative growth involving 
both the lips of cervix and upper two-third of the vagina. The right 
parametrium was free while the left parametrium was involved up 
to the lateral pelvic wall. A punch biopsy was done, and 
histopathology report was non-keratinizing squamous cell 
carcinoma. Routine laboratory, chest X-ray and CECT whole 
abdomen were done. The final diagnosis was squamous cell 
carcinoma from the cervix which was FIGO IIIB. 
She was treated on Tele-cobalt unit with two parallel opposed antero-
posterior fields to a dose of 46Gy in 23 fractions from 01/12/2014 
until 31/12/2014. She was given Inj. Cisplatin (40 mg/m2
She underwent below-elbow amputation by an orthopedic surgeon 
in Sir Sunder Lal Hospital, Banaras Hindu University. 
) weekly 
concurrently with radiotherapy. Subsequent to external beam 
radiotherapy she was treated with low dose rate brachytherapy to a 
dose of 29Gy in 22 hrs to point A. At the end of the treatment, she did 
not have any residual disease on clinical evaluation. Just after 10 days 
of completion of her treatment she started developing blackening of 
her left hand, which progressed very rapidly. On clinical 
examination, she had intense black skin involving her left hand until 
her wrist. The implicated area was dry, non-tender and had absent 
sensation to touch. There was no discharge or any signs of 
inflammation in the concerned area (fig. 1). Ulnar and brachial 
pulses were present. The radial pulses were absent, and her hand was 
cold and edematous. She could move her fingers to a small extent. 
Color Doppler of upper limbs, revealed that her arterial walls were 
thickened, which was suggestive of atherosclerosis. 2D 
echocardiography was normal. Platelet count, D-Dimer, bleeding time, 
clotting time, PT and INR was within the normal range. CT 
angiography of the left upper limb showed that the left subclavian & 
axillary arteries, brachial artery, bifurcation of the brachial artery, 
radial and ulnar arteries were normal. Superficial and deep palmer 
arches of the left hand showed faint opacification with multiple small 
collateral channels arising from distal radial & ulnar arteries (fig. 2). 
Necessary permission for reporting her information was taken from 
the patient. 
DISCUSSION 
The index patient developed dry gangrene of her left hand just after 
her treatment with radiotherapy with concurrent cisplatin. She did 
not have coagulopathy or any cardiac disease. CT angiography 
showed signs of vasculitis in the distal arteries. In all probabilities, it 
was cisplatin, which was the culprit. 
The exact mechanism of vascular damage by cisplatin is still not well 
known. The likely mechanisms by which cisplatin induces vascular 
events are endothelial dysfunction, vasospasm, and autonomic 
dysfunction [1]. 
Vogelzang et al. reported the incidence of Raynaud’s phenomenon in 
21% of patients with testicular cancer treated with Vinblastine and 
Bleomycin, and in 38% of patients receiving a similar regimen 
incorporating cisplatin [2]. Our patient did not have symptoms and 
signs of Raynaud’s phenomenon. Cisplatin is a known causative 
agent for ischemic vascular complications involving major arteries 
usually in patients with the high risk factor for atherosclerosis [3]. 
 There are few case reports, which suggest that cisplatin based 
chemotherapies were responsible for myocardial infarction in the 
absence of any risk factor for atherosclerosis [4]. Our patient was 
young, thin built and had no history of smoking. 
Hypomagnesemia, a side-effect of cisplatin, is known to potentiate 
arterial spasm. Autonomic dysfunction with regards to increased 
alpha-adrenergic tone has been reported with cisplatin [5]. This seems 
the unlikely cause in our patient as all of our patients routinely receive 
a magnesium supplement through intra venous route. 
In our case, hypoperfusion which could have been due to arterial 




Fig. 1: Photograph of the patient with gangrene 
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Fig. 2: CT angiography of the upper limb 
 
CONCLUSION 
Documentation and reporting of these events is important to 
develop guidelines for risk assessment of vascular damage 
whenever cisplatin is planned for treatment. In conditions where 
carboplatin is equally efficacious to Cisplatin, one can decide to 
consider the former to reduce the risk of such catastrophic events. 
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